Just Published: Adjuvant pembrolizumab after resected stage III melanoma led to a 5-year recurrence-free survival of 55.4%, compared with 38.3% in patients treated with placebo. Read more in NEJM Evidence: https://eviden.cc/3x6Wg6l #ESMO22 | The New England Journal of Medicine

Patients with stage III or IV melanoma can benefit from adjuvant pembrolizumab. Whether outcomes with neoadjuvant plus adjuvant pembrolizumab would be better than those with adjuvant therapy alone is unknown. New research findings are summarized in a short video. https://nej.md/3YaD6qN | The New England Journal of Medicine

Senator Bernie Sanders is questioning the high cost of cancer drugs in the U.S. compared to other countries. He highlights that Merck charges $206,000 annually for Keytruda in the U.S., while it's $80,000 in Germany and $42,000 in Japan. Similarly, Johnson & Johnson's Darzalex costs $188,000 in the U.S., but only $82,000 in Canada and $79,000 in Japan. Bristol-Myers Squibb's Opdivo is priced at $204,000 in the U.S., compared to $73,000 in Germany and $48,000 in Japan. Sanders points out that the